Clinical Trials
9
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (9 trials with phase data)• Click on a phase to view related trials
Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic Fibrosis
- First Posted Date
- 2022-02-07
- Last Posted Date
- 2024-06-17
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 13
- Registration Number
- NCT05225805
- Locations
- 🇺🇸
University of Kansas School of Medicine, Kansas City, Kansas, United States
🇺🇸Boston Children's Hospital, Boston, Massachusetts, United States
🇺🇸New York Medical College, Valhalla, New York, United States
4-way Crossover QT Evaluation in Healthy Subjects
- Conditions
- Cardiac Repolarization in Healthy Subjects
- Interventions
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2019-03-06
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 41
- Registration Number
- NCT03709927
- Locations
- 🇺🇸
Pharmaron, Baltimore, Maryland, United States
PK Study of Single-Dose ZTI-01 in Children (<12 Years of Age)
- Conditions
- Pediatric ALL
- Interventions
- Drug: ZTI-01 100 mg/kgDrug: ZTI-01 75 mg/kg
- First Posted Date
- 2018-10-17
- Last Posted Date
- 2023-09-15
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 21
- Registration Number
- NCT03709914
- Locations
- 🇺🇸
Children's Hospital of Orange County, Orange, California, United States
🇺🇸Rady Children's Hospital, San Diego, California, United States
🇺🇸Kosair Charities Pediatric Clinical Research Unit, Louisville, Kentucky, United States
A Study to Assess Mass Balance Recovery, Metabolite Profile and Identification of IV and Oral 14C-BC-3781
- First Posted Date
- 2017-04-27
- Last Posted Date
- 2018-04-03
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 10
- Registration Number
- NCT03131141
- Locations
- 🇬🇧
Quotient Clinical, Nottingham, United Kingdom
Study to Compare Lefamulin to Moxifloxacin for the Treatment of Adults With Pneumonia
- Conditions
- Community Acquired Pneumonia
- Interventions
- First Posted Date
- 2016-06-27
- Last Posted Date
- 2019-10-23
- Lead Sponsor
- Nabriva Therapeutics AG
- Target Recruit Count
- 738
- Registration Number
- NCT02813694
- Locations
- 🇺🇸
1080, Beverly Hills, California, United States
🇺🇸Site 1065, Fresno, California, United States
🇺🇸1078, Northridge, California, United States
- Prev
- 1
- 2
- Next